天津医药

• 临床研究 • 上一篇    下一篇

胰高血糖素肽1对糖尿病伴高血压患者血压变异性的影响

王少清1,臧丽1,汪力1,高芳1,付平2   

  1. 1. 成都医学院第一附属医院
    2. 四川大学华西医院
  • 收稿日期:2013-12-26 修回日期:2014-02-25 出版日期:2014-08-15 发布日期:2014-08-15
  • 通讯作者: 王少清

Effects of Glucagon Peptide-1on Blood Pressure Variability in Diabetic Hypertensive Patients

WANG Shaoqing ,ZANG Li ,WANG Li ,GAO Fang ,FU Ping   

  • Received:2013-12-26 Revised:2014-02-25 Published:2014-08-15 Online:2014-08-15
  • Contact: WANG Shaoqing

PDF (PC)

2709

摘要：

【摘要】目的  探讨胰高血糖素肽1（GLP-1）对2型糖尿病伴高血压患者血压变异性（BPV）的影响。方法  选取糖尿病伴高血压患者120例，使用GLP-1对其进行治疗，检测患者使用前及使用6个月后体质指数（BMI）、空腹血糖、糖化血红蛋白、血清肌酐、血脂等，并进行24h动态血压监测，得到短时BPV。比较治疗前后的相关指标。结果   使用GLP-1后6个月，患者空腹血糖（mmol/L :7.12±0.64vs9.19±2.78）、糖化血红蛋白（%:7.00±0.14vs8.28±1.32）、BMI（kg/m2: 19.30±3.24vs24.50±4.53）较治疗前下降（P<0.05），达到控制目标。24h收缩压（mmHg :135.02±16.57vs139.52±15.60）、白昼收缩压（mmHg:132.50±14.60vs136.44±14.24）、24h收缩压变异性（mmHg:12.20±1.44vs
12.73±1.66）、白昼收缩压变异性（mmHg:11.11±1.48vs11.74±1.52）、白昼舒张压变异性（mmHg:7.03±1.42vs7.43±1.45）也降低（P<0.05）。结论  GLP-1可降低糖尿病伴高血压患者的BPV。

关键词: 胰高血糖素肽1, 糖尿病, 2型, 高血压, 血压变异性

Abstract:

[Abstract] Objective   To investigate the role of glucagon peptide-1(GLP-1) in blood pressure variability (BPV) in
diabetic hypertensive patients.Methods   A total of120diabetic hypertensive patients were included in this study. GLP-1 was used for the treatment. The values of body mass index (BMI), fasting blood glucose, glycosylated hemoglobin, creatine and24-hour ambulatory blood pressure (BP) monitoring were detected before and after treatment with GLP-1for six months. The clinical indices were compared before and after treatment.Results   The values of fasting blood glucose (mmol/L:7.12±0.64vs9.19±2.78), glycosylated hemoglobin (%:7.00±0.14vs8.28±1.32) and BMI (kg/m2
:19.30±3.24vs24.5±4.53) were de?creased to the normal level after GLP-1treatment for six months (P<0.05). There were significant decrease in the 24-h sys?tolic BP (mmHg:135.02±16.57vs139.52±15.60), daytime systolic BP (mmHg:132.5±14.6vs136.44±14.24), 24-h systolic BP variability (mmHg:12.20±1.44vs12.73±1.66), daytime systolic BP variability (mmHg:11.11±1.48vs11.74±1.52), and daytime diastolic BP variability (mmHg:7.03±1.42vs7.43±1.45) after GLP-1treatment for six months (P<0.05). Conclu?sion   GLP-1can decrease BPV in diabetic hypertensive patients.

Key words: Glucagon peptide-1, diabetes mellitus, type2, hypertension, blood pressure variability